Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine cover art

TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine

TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine

Listen for free

View show details
About this listen
SHOW NOTES
- Dear TSC Alliance Leadership and Natural History Database Steering Committee,.pdf
- TSC Alliance contact: biosample@tscalliance.org
- Host contact: Jill Woodworth (pjlacy6@gmail.com)
- MA AG consumer complaint form: mass.gov/how-to/file-a-consumer-complaint
- Apertura Gene Therapy press release (May 2026)
- TSC Alliance NHD page: tscalliance.org
- Van Andel Institute Biorepository: Grand Rapids, MI
- Key terms: AAV, TSC1, TSC2, vector sizing, DRG toxicity, antibody neutralization, 15-year FDA follow-up mandate
---
KEY DEFINITIONS
*AAV Capsid Delivery Platform: An adeno-associated virus (AAV) vector system engineered to deliver functional genetic material into host cells. In this context, it utilizes a viral shell (capsid) to cross specific biological barriers and target neural tissues. Key operational constraints and clinical considerations include:
*Packaging Limits: AAV vectors have a strict genetic payload capacity of approximately 4.7 kilobases total (including ITRs), leaving roughly 4.4 kilobases for the transgene cassette. Genes exceeding this length (such as full-length TSC2, at ~4.3 kb coding sequence plus necessary promoter and polyA signals) present significant packaging challenges.
*Immune Response & Irreversibility:** Exposure to an AAV capsid triggers neutralizing antibody production by the patient's immune system, permanently barring subsequent administration of AAV-based treatments.
*Monitoring Requirements: Regulatory standards (such as FDA mandates) require extended long-term follow-up monitoring—typically lasting up to 15 years—to evaluate long-term safety, potential hepatotoxicity, and dorsal root ganglion (DRG) toxicity.
I discuss the TSC gene therapy agreement and the TSC Natural History Database (NHD), raising questions about consent, data governance, and long-term impacts on families. I explains the NHD’s scope (running since 2006 with 2,700+ participants, clinical histories and biosamples stored at Van Andel Institute, and thousands of samples distributed to researchers) and critiques the May 2026 TSC Alliance partnership with for-profit Apertura Gene Therapy, backed by Deerfield Management, to develop an AAV gene replacement therapy delivering TSC1/TSC2 to the brain. I outline concerns about lack of reconsent when minors become adults, unclear withdrawal processes, financial protections for participants, and under-communicated risks of AAV therapies (high cost, permanent antibody barrier to future AAV dosing, 15-year monitoring, and TSC2 packaging constraints). I describe a certified letter demanding written answers and offers steps for parents to request consent forms, ask about withdrawal, and file complaints if needed.

00:00 Intro and Big Questions
01:57 What We Signed
02:34 Inside the NHD Database
03:47 Apertura Partnership Explained
04:59 Consent and Governance Gaps
06:30 Gene Therapy Risks Breakdown
09:29 My Certified Letter
09:37 Five Demands for Transparency
12:35 What You Can Do Now
14:48 Final Thoughts and Wrap Up
https://aperturagtx.com/news/apertura-gene-therapy-and-the-tsc-alliance-announce-collaboration-to-advance-gene-therapy-programs-designed-to-treat-tuberous-sclerosis-complex-tsc/
https://www.prnewswire.com/news-releases/apertura-gene-therapy-showcases-the-progress-of-its-novel-human-transferrin-receptor-aav-capsid-tfr1-capx-and-preclinical-programs-for-tuberous-sclerosis-complex-tsc-at-the-american-society-of-gene-and-cell-therapy-asgct-ann-302448607.html
https://www.prnewswire.com/news-releases/tsc-alliance-and-apertura-gene-therapy-complete-preclinical-pilot-study-evaluating-aav-gene-therapy-approach-designed-for-tsc1-302838523.html

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.
adbl_web_anon_alc_button_suppression_t1
No reviews yet